Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2605-2614

  Takagi, Satoshi ^a   Oh Hara, Tomoko ^a   Sato, Shigeo ^a   Gong, Bo ^a,b   Takami, Miho ^a   Fujita, Naoya ^a,b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Aggrus podoplanin; bladder cancer; platelet aggregation

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MS 1; MONOCLONAL ANTIBODY P2 0; PODOPLANIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PODOPLANIN GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOCYTE AGGREGATION; TISSUE MICROARRAY;

AGGRUS/PODOPLANIN; BLADDER CANCER; PLATELET AGGREGATION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED ICR; PLATELET AGGREGATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84896401362     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28602     Document Type: Article

References (39)

1. Hoffman AM, Cairns P,. Epigenetics of kidney cancer and bladder cancer. Epigenomics 2011; 3: 19-34.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Garcia-Closas M, Rothman N, Figueroa JD, et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res 2012; 73: 2211-20.
4. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet 2009; 374: 239-49.
5. Said N, Theodorescu D,. Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev 2009; 28: 327-33.
6. Shokeir AA,. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int 2004; 93: 216-20.
7. Zhong M, Gersbach E, Rohan SM, et al. Primary adenocarcinoma of the urinary bladder: differential diagnosis and clinical relevance. Arch Pathol Lab Med 2013; 137: 371-81.
8. Said N, Smith S, Sanchez-Carbayo M, et al. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 2011; 121: 132-47.
9. Overdevest JB, Knubel KH, Duex JE, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A 2012; 109: E3588-96.
10. Smith SC, Nicholson B, Nitz M, et al. Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol 2009; 174: 371-9.
11. Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003; 278: 51599-605.
12. Gay LJ, Felding-Habermann B,. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-34.
13. Gasic GJ, Gasic TB, Stewart CC,. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52.
14. Karpatkin S, Pearlstein E, Salk PL, et al. Role of platelets in tumor cell metastasis. Ann N Y Acad Sci 1981; 370: 101-18.
15. Kunita A, Kashima TG, Morishita Y, et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007; 170: 1337-47.
16. Fujita N, Takagi S,. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. J Biochem 2012; 152: 407-13.
17. Astarita JL, Acton SE, Turley SJ,. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 2012; 3: 1-11.
18. Kato Y, Kaneko M, Sata M, et al. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005; 26: 195-200.
19. Shimada Y, Ishii G, Nagai K, et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 2009; 100: 2054-9.
20. Kawase A, Ishii G, Nagai K, et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008; 123: 1053-9.
21. Atsumi N, Ishii G, Kojima M, et al. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 2008; 373: 36-41.
22. Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007; 282: 25993-6001.
23. Christou CM, Pearce AC, Watson AA, et al. Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 2008; 411: 133-40.
24. Suzuki-Inoue K, Fuller GL, García A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107: 542-9.
25. Suzuki-Inoue K,. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem 2011; 150: 127-32.
26. Lowe KL, Navarro-Nunez L, Watson SP,. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012; 129: S30-7.
27. Nakazawa Y, Sato S, Naito M, et al. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 2008; 112: 1730-9.
28. Tsuruo T, Yamori T, Naganuma K, et al. Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. Gann 1984; 75: 193-8.
29. Takagi S, Simizu S, Osada H,. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 2009; 69: 1502-8.
30. Watanabe M, Okochi E, Sugimoto Y, et al. Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res 1988; 48: 6411-6.
31. Nakazawa Y, Takagi S, Sato S, et al. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci 2011; 102: 2051-7.
32. Takagi S, Sato S, Oh-Hara T, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013; 8: e73609.
33. Kato Y, Sasagawa I, Kaneko M, et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004; 23: 8552-6.
34. Chuang WY, Yeh CJ, Wu YC, et al. Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol 2009; 24: 1021-7.
35. Chao YK, Chuang WY, Yeh CJ, et al. Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients. J Surg Oncol 2012; 105: 183-8.
36. O'Donnell MA,. Advances in the management of superficial bladder cancer. Semin Oncol 2007; 34: 85-97.
37. Friedrich RE, Bartel-Friedrich S, Hagel C,. Expression of podoplanin in primary and metastatic poorly differentiated and undifferentiated carcinomas of the head and neck. Anticancer Res 2012; 32: 2019-22.
38. Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer. J Natl Compr Canc Netw 2013; 11: 446-75.
39. Abe S, Morita Y, Kaneko MK, et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 2013; 190: 6239-49.